Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes

Published:2016-03-02 Issue:5 Volume:7 Page:744-750
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Sarashina Akiko¹,Friedrich Christian²,Crowe Susanne²,Patel Sanjay³,Graefe-Mody Ulrike²,Hayashi Naoyuki⁴,Horie Yoshiharu⁵

Affiliation:

1. Clinical Pharmacokinetics/Pharmacodynamics Department; Nippon Boehringer Ingelheim Co., Ltd; Hyogo Japan

2. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

3. Boehringer Ingelheim Ltd; Bracknell UK

4. Clinical Research Department; Nippon Boehringer Ingelheim Co., Ltd; Tokyo Japan

5. Medical Data Service Department; Nippon Boehringer Ingelheim Co., Ltd; Tokyo Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12482/fullpdf

Reference27 articles.

1. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas;Seino;J Diabetes Investig,2013

2. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors;Thomas;J Pharmacol Exp Ther,2008

3. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes;Deacon;Expert Opin Investig Drugs,2010

4. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats;Fuchs;Biopharm Drug Dispos,2009

5. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients;Heise;Diabetes Obes Metab,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real World Study of Effectiveness of Gemigliptin Add-On Therapy in Type 2 Diabetes Mellitus;Clinical Diabetology;2022-06-30

2. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting;Diabetes Therapy;2022-03-25

3. The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study;BMC Medicine;2022-01-26

4. Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans;Journal of Pharmaceutical Sciences;2020-07

5. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials;Advances in Therapy;2017-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3